Clinics, hospitals and available options
Ketamine-assisted therapy is an emerging intervention in mental health, especially relevant for treatment-resistant depression and other complex conditions. In Spain, access is provided through specialised private clinics and, more restrictively, through the public hospital system.
Below is a summary of the main options currently identifiable, along with the key differences between the various types of ketamine treatment.
Clínica Synaptica
Clínica Synaptica is a centre specialising in psychedelic therapy, based in Barcelona, that positions itself as one of the first and best-known in Spain to offer ketamine-assisted therapy combined with professional psychotherapy. Its clinical team is made up of professionals with experience in mental health and integrative approaches that combine pharmacotherapy and psychotherapy to address complex conditions such as depression, anxiety, trauma and associated symptoms, including suicidal thoughts.
At Synaptica, each treatment is personalised to the patient’s individual needs, starting with a prior clinical assessment to determine whether ketamine-assisted therapy is suitable and safe. The approach combines ketamine administration sessions with structured psychotherapeutic support to maximise therapeutic benefit and encourage lasting change in mental health
Show mapDr. Scheib
One of the most prominent private providers is the group linked to Dr. Scheib, known as Ketamin Plus, with a presence in different parts of Spain and an established clinical track record.
In Mallorca, treatments are offered at the Dr. Scheib Institute Mallorca, at Calle Camilo José Cela 20 in Palma de Mallorca. Since 2015 this centre has combined intravenous ketamine infusions with intensive psychotherapy. The therapeutic approach is aimed at depression, anxiety, psychological trauma, burnout, obsessive-compulsive disorder and chronic pain, including conditions such as fibromyalgia.
Show mapClínica Humanline
In Sotogrande, Cádiz, meanwhile, care is channelled through the Humanline Clinic. This centre holds specialised consultations and ketamine infusion treatments aimed at depression, OCD, post-traumatic stress disorder and addictive disorders. As in Mallorca, treatment is set out as an integrated process alongside psychotherapy.
Show mapPossible options in hospitals and university centres
Clínica Universidad de Navarra
The Clínica Universidad de Navarra, with sites in Pamplona and Madrid, is a leading university hospital that could offer ketamine-related treatments in very specific contexts and under strict supervision.
Although the public information available usually focuses on the hospital use of ketamine as an anaesthetic, centres of this level can give treatments such as intravenous ketamine or intranasal esketamine in complex cases of resistant depression. However, it is essential to contact the centre directly to confirm whether these specific clinical services are available.
Show mapEsketamine (Spravato) treatment in the National Health System
Since the end of 2022, Spain’s National Health System has funded esketamine treatment in nasal spray format, marketed as Spravato. This drug is a derivative of ketamine and has a very specific indication.
It is approved exclusively for adult patients with treatment-resistant major depression who have not responded adequately to several previous antidepressants. It is administered only in hospitals and under strict medical supervision. It is also not dispensed in community pharmacies, since the patient must remain under observation after each administration.
Access to this treatment is through referral from the psychiatry services of public hospitals that have implemented the relevant programme.
Important considerations about ketamine-assisted therapy
First, any treatment with ketamine or esketamine requires specialised medical supervision. A prior psychiatric assessment, a clear indication and adequate follow-up are essential.
It is also worth distinguishing between two main modalities. On the one hand, intravenous ketamine infusions, which are usually used in private clinics for various indications off-label. On the other, intranasal esketamine, which has a specific regulatory approval for resistant depression and is given exclusively in hospitals.
Availability and cost can also vary significantly. Treatment at private clinics is not always covered by health insurance and is a direct cost to the patient. Spravato, by contrast, is funded by the national health system, though only for very specific clinical profiles.
Finally, research on ketamine continues to advance. New indications, optimised protocols and possible alternative formulations, including oral routes, are currently being studied, although these are not yet part of standard clinical practice.
Final recommendation
Ketamine-assisted therapy can be a relevant therapeutic option for certain patients, especially in cases of resistant depression and other complex conditions. However, it should always be used in an appropriate medical context, with clear information on indications, risks, legal framework and costs.
For this reason, we recommend contacting the specialist clinics mentioned directly, or consulting a reference doctor or psychiatrist to assess whether the treatment is suitable and to learn about the options available in each case.



